Myo-inositol: a potential prophylaxis against premature onset of labour and preterm birth

Page view(s)
5
Checked on May 10, 2024
Myo-inositol: a potential prophylaxis against premature onset of labour and preterm birth
Title:
Myo-inositol: a potential prophylaxis against premature onset of labour and preterm birth
Journal Title:
Nutrition Research Reviews
Publication Date:
16 September 2021
Citation:
Sharma, N., Watkins, O. C., Chu, A. H. Y., Cutfield, W., Godfrey, K. M., Yong, H. E. J., & Chan, S.Y. (2021). Myo-inositol: a potential prophylaxis against premature onset of labour and preterm birth. Nutrition Research Reviews, 1–9. doi:10.1017/s0954422421000299
Abstract:
Abstract The incidence of preterm birth (PTB), delivery before 37 completed weeks of gestation, is rising in most countries. Several recent small clinical trials of myo-inositol supplementation in pregnancy, which were primarily aimed at preventing gestational diabetes, have suggested an effect on reducing the incidence of PTB as a secondary outcome, highlighting the potential role of myo-inositol as a preventive agent. However, the underlying molecular mechanisms by which myo-inositol might be able to do so remain unknown; these may occur through directly influencing the onset and progress of labour, or by suppressing stimuli that trigger or promote labour. This paper presents hypotheses outlining the potential role of uteroplacental myo-inositol in human parturition and explains possible underlying molecular mechanisms by which myo-inositol might modulate the uteroplacental environment and inhibit preterm labour onset. We suggest that a physiological decline in uteroplacental inositol levels to a critical threshold with advancing gestation, in concert with an increasingly pro-inflammatory uteroplacental environment, permits spontaneous membrane rupture and labour onset. A higher uteroplacental inositol level, potentially promoted by maternal myo-inositol supplementation, might affect lipid metabolism, eicosanoid production and secretion of pro-inflammatory chemocytokines that overall dampen the pro-labour uteroplacental environment responsible for labour onset and progress, thus reducing the risk of PTB. Understanding how and when inositol may act to reduce PTB risk would facilitate the design of future clinical trials of maternal myo-inositol supplementation and definitively address the efficacy of myo-inositol prophylaxis against PTB.
License type:
Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Funding Info:
This research / project is supported by the National Medical Research Council - Clinician Scientist Award
Grant Reference no. : NMRC/CSA-INV/0010/2016

This research / project is supported by the National Medical Research Council - Clinician Scientist Award
Grant Reference no. : MOH-CSAINV19nov-0002

This research / project is supported by the National Institute for Health Research - NIHR Senior Investigator
Grant Reference no. : NF-SI-0515-10042

This research is supported by core funding from: A*STAR, Singapore Institute for Clinical Sciences
Grant Reference no. :

1) Medical Research Council - (MC_UU_12011/4) 2) NIHR Southampton Biomedical Research Centre - (IS-BRC-1215-20004) 3) European Union (Erasmus+ Programme ImpENSA 598488-EPP-1-2018-1-DE-EPPKA2- CBHE-JP) 4) British Heart Foundation - (RG/15/17/3174) 5) National University of Singapore (no specific grant number) 6) National University Health System Singapore (no specific grant number)
Description:
This article has been published in a revised form in Nutrition Research Reviews [http://doi.org/10.1017/S0954422421000299]. This version is published under a Creative Commons CC-BY-NC-ND. No commercial re-distribution or re-use allowed. Derivative works cannot be distributed. © copyright holder
ISSN:
0954-4224
1475-2700
Files uploaded:

File Size Format Action
accepted-manuscript.pdf 1.26 MB PDF Open